Page last updated: 2024-09-05

enzastaurin and Neoplasms, Pleural

enzastaurin has been researched along with Neoplasms, Pleural in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Biffo, S; Brina, D; Grosso, S; Miluzio, A; Murer, B; Mutti, L; Oliveto, S; Pesce, E; Ricciardi, S	1
Faoro, L; Husain, AN; Kindler, HL; Loganathan, S; Modi, R; Salgia, R; Seiwert, T; Tretiakova, M; Vokes, EE; Westerhoff, M	1
Bradford, D; Bufill, J; Casey, EM; Fisher, W; Hanna, N; Harb, W; Latz, JE; Li, X; Nattam, S; Patel, J; Wu, J	1

Trials

1 trial(s) available for enzastaurin and Neoplasms, Pleural

Article	Year
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11 Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Placebos; Pleural Neoplasms; Survival Rate; Treatment Outcome	2010

Article

Year

Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11

Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Placebos; Pleural Neoplasms; Survival Rate; Treatment Outcome

2010

Other Studies

2 other study(ies) available for enzastaurin and Neoplasms, Pleural

Article	Year
Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo. Oncotarget, 2015, Nov-10, Volume: 6, Issue:35 Topics: Adenosine Triphosphate; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Eukaryotic Initiation Factors; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Indoles; Mesothelioma; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Pleural Neoplasms; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Stability; RNA Interference; RNAi Therapeutics; Signal Transduction; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays	2015
Protein kinase C beta in malignant pleural mesothelioma. Anti-cancer drugs, 2008, Volume: 19, Issue:9 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Humans; Indoles; Inhibitory Concentration 50; Mesothelioma; Phorbol Esters; Phosphorylation; Pleural Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Survival Rate	2008

Article

Year

Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.

Oncotarget, 2015, Nov-10, Volume: 6, Issue:35

Topics: Adenosine Triphosphate; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Eukaryotic Initiation Factors; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Indoles; Mesothelioma; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Pleural Neoplasms; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Stability; RNA Interference; RNAi Therapeutics; Signal Transduction; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays

2015

Protein kinase C beta in malignant pleural mesothelioma.

Anti-cancer drugs, 2008, Volume: 19, Issue:9

Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Humans; Indoles; Inhibitory Concentration 50; Mesothelioma; Phorbol Esters; Phosphorylation; Pleural Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Survival Rate

2008